Rhelion Life Sciences Unit Expands Supply Agreement with University of Chieti-Pescara for PEX010

09:48 AM EDT, 09/25/2026 (MT Newswires) -- Rhelion Life Sciences' (RHEL.CN) Filament Health unit expanded its supply and license agreement with the University G. d'Annunzio of Chieti-Pescara for the supply of PEX010, its psilocybin drug candidate, to TEMPO, a clinical trial of psilocybin for treatment-resistant depression conducted at the psychiatric clinic of the Italian university, it said Friday. The expanded supply agreement supports an increase in the number of trial participants following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, it said. Filament also provides regulatory support for the trial and release of PEX010 for use in the European Union, it added. The University is the sponsor of the trial. Shares of Rhelion were last seen unchanged at CA$0.03 on the Canadian Securities Exchange.